End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 CNY | +1.05% |
|
+3.05% | -51.08% |
26/06 | Walvax Biotechnology Ends Vaccine Development Deal With Abogen Biotechnology | MT |
18/06 | Walvax Terminates Coronavirus Vaccine Trials Due to Mutations | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.08% | 250.15Cr | |
+2.08% | 9.52TCr | |
-0.13% | 3.75TCr | |
-10.43% | 3.38TCr | |
+77.76% | 2.82TCr | |
-14.82% | 1.56TCr | |
-3.06% | 1.36TCr | |
-12.76% | 1.15TCr | |
+181.73% | 1.08TCr | |
-53.92% | 923.34Cr |
- Stock Market
- Equities
- 300142 Stock
- News Walvax Biotechnology Co., Ltd.
- Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial